Response rates of pazopanib therapy in metastatic soft tissue sarcoma using real‑world data

Söylemez,Cem Murat; Gürsoy,Pinar; Şanli,Ulus Ali

doi:10.3892/ol.2024.14848

March-2025 Volume 29 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2025 Volume 29 Issue 3

Full Size Image

Article

Response rates of pazopanib therapy in metastatic soft tissue sarcoma using real‑world data

Authors:
- Cem Murat Söylemez
- Pinar Gürsoy
- Ulus Ali Şanli
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, University of Health Science Izmir Tepecik Research and Training Hospital, Bornova, Izmir 35110, Turkey, Department of Medical Oncology, Ege University Faculty of Medicine, Bornova, Izmir 35100, Turkey
Article Number: 102
|
Published online on: December 17, 2024

https://doi.org/10.3892/ol.2024.14848
Expand metrics +

Abstract

The present study was a retrospective single‑center study. A total of 81 patients diagnosed with metastatic soft tissue sarcoma were included who received pazopanib therapy. Clinical data, including age at diagnosis, histological subtype, treatments received before pazopanib, number of metastatic sites at the time of initiation of treatment, progression‑free survival and overall survival time under pazopanib treatment, side effects and response evaluation in follow‑up imaging after initiation of pazopanib therapy, were recorded. The 81 patients had 11 different histological subtypes. The synovial sarcoma, leiomyosarcoma and pleomorphic sarcoma groups included 51 patients in total. The median overall survival time in the entire study cohort was 46 months, and the median progression‑free survival time was 5 months. The clinical response rate was 46.3%. Patients with hemangioendothelioma and alveolar soft part sarcoma exhibited an improved response to treatment compared with that of patients with other subtypes. Line of therapy and tumor grade were not significantly associated with progression‑free survival or clinical response. It was concluded that, regardless of subtype, patients with a low tumor grade and a small number of metastatic sites exhibited an improved response; although the difference in response for patients with a low tumor grade was not significant. In addition, administering the treatment as a second‑ or third‑line therapy appeared to be more appropriate compared with administering it as a later‑line therapy; however, this difference was not found to be statistically significant. Therefore, pazopanib should be evaluated as an option for a selected group of patients in whom these factors present together. A further advantage of pazopanib demonstrated was that treatment tolerance was generally good.9

View Figures

View References

1	Burningham Z, Hashibe M, Spector L and Schiffman JD: The epidemiology of sarcoma. Clin Sarcoma Res. 2:142012. View Article : Google Scholar : PubMed/NCBI
2	Ramu EM, Houdek MT, Isaac CE, Dickie CI, Ferguson PC and Wunder JS: Management of softtissue sarcomas; treatment strategies, staging, and outcomes. SICOT J. 3:20170102017. View Article : Google Scholar
3	Gebhardt MC: Surgical resection of primary soft tissue sarcoma of the extremities. UpToDate:. https://www.uptodate.com/contents/surgical-resection-of-primary-soft-tissue-sarcoma-of-the-extremities?csi=713bac06-a2a1-474f-85e3-00037d327ff8&source=contentShareJuly 29–2021
4	George S and Razak ARA: Overview of the initial treatment of metastatic soft tissue sarcoma. UpToDate:. https://www.uptodate.com/contents/overview-of-the-initial-treatment-of-metastatic-soft-tissue-sarcoma?csi=fac78e3c-5a2f-44ae-a398-db74f544d104&source=contentShareAugust 12–2023
5	Nguyen DT and Shayahi S: Pazopanib: Approval for soft-tissue sarcoma. J Adv Pract Oncol. 4:53–57. 2013.PubMed/NCBI
6	Koehler K, Liebner D and Chen JL: TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol. 27:539–543. 2016. View Article : Google Scholar : PubMed/NCBI
7	Lochner J, Menge F, Vassos N, Hohenberger P and Kasper B: Prognosis of patients with metastatic soft tissue sarcoma: Advances in recent years. Oncol Res Treat. 43:613–619. 2020. View Article : Google Scholar : PubMed/NCBI
8	Kasper B, Sleijfer S, Litière S, Marreaud S, Verweij J, Hodge RA, Bauer S, Kerst JM and van der Graaf WTA: Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: Subanalysis of two European organisation for research and treatment of cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol. 25:719–724. 2014. View Article : Google Scholar : PubMed/NCBI
9	Stacchiotti S, Mir O, Cesne AL, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, et al: Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. Oncologist. 23:62–70. 2018. View Article : Google Scholar : PubMed/NCBI
10	Le Cesne A, Bauer S, Demetri GD, Han G, Dezzani L, Ahmad Q, Blay JY, Judson I, Schöffski P, Aglietta M, et al: Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. BMC Cancer. 19:7942019. View Article : Google Scholar : PubMed/NCBI
11	Kim SK, Kim JH, Kim SH, Lee YH, Han JW, Baek W, Woo HY, Jeon MK and Kim HS: PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma. BMC Cancer. 21:3362021. View Article : Google Scholar : PubMed/NCBI
12	Cho HJ, Yun KH, Shin SJ, Lee YH, Kim SH, Baek W, Han YD, Kim SK, Ryu HJ, Lee J, et al: Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: A phase II trial. Nat Commun. 15:6852024. View Article : Google Scholar : PubMed/NCBI
13	Suehara Y, Kohsaka S, Yamaguchi S, Hayashi T, Kurihara T, Sano K, Sasa K, Akaike K, Ueno T, Kojima S, et al: Assessment of predictive biomarkers of the response to pazopanib based on an integrative analysis of high-grade soft-tissue sarcomas: Analysis of a tumor sample from a responder and patients with other soft-tissue sarcomas. Clin Orthop Relat Res. 478:2461–2476. 2020. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Response rates of pazopanib therapy in metastatic soft tissue sarcoma using real‑world data

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles